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Results: Overall, 1082 target lesions were identified. The target lesions were A type
in 111 cases (10.3%), B1 in 201 (18.6%), B2 in 252 (23.3%), and C in 518 (47.9%).
Complete follow-up was available for 99.3% of the patients at 180 days, 99.1% at 360
days, and 99.1% at 540 days. A total of 17 deaths occurred during the 180 days (2.3%),
25 deaths occurred during the 360 days, and 27 deaths occurred during the 540 days.
In none of these cases, death occurred as an unexpected, sudden episode that could be
attributable to stent thrombosis. no patient had recurrent myocardial infarction, and
there were no additional reinterventions. Also, 5 thrombosis events by ARC definition
at 18-months were documented. The average duration of clopidogrel treatment was
180 days. The cumulative rates of major adverse cardiac events were 2.0% at 180 days,
3.9% at 1 year, and 4.2% at 18 months. Overall rate of stent thrombosis was 0.87% at
18 months. The rates of acute, subacute, late, and very late stent thrombosis were 0.1%,
0.38%, 0.34%, and 0.05%, respectively. Angiographic follow-up, performed in 974
(31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss
of 0.21 ± 0.39 mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment.
Conclusion: This multicenter registry documents satisfactory safety and efficacy
profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis
up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent.
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Background: Multislice computed tomography (MSCT) coronary angiography has
emerged as a non-invasive diagnostic modality to evaluate coronary artery disease.
However, visualization or evaluation of the in-stent lumen by MSCT is challenging
owing to the blooming artefact caused by metallic stent struts. The feasibility and
accuracy of the use of MSCT in the analysis of radiolucent bioresorbable scaffolds
could indicate a new era for non-invasive assessment of patients treated with
radiolucent devices.
Methods: The ABSORB Cohort B trial enrolled 101 patients at 12 sites in the
European and Asia Pacific regions between March and November 2009. The current
aim is to assess, by MSCT, the midterm results at 18 months in terms of patency and
absence of binary restenosis of the ABSORB bioresorbable everolimus eluting vascular
scaffold (Abbott Vascular, Santa Clara, CA, USA).
Results: In the smaller ABSORB Cohort A study, we have previously demonstrated
that non-invasive imaging of the ABSORB scaffold patency with MSCT is feasible
without the artifacts associated with conventional metal stents. In the ABSORB Cohort
B trial, clinical data up to 1 year for the full cohort of 101 patients are currently
available. In these 101 patients, 1 year results showed an ID-MACE rate of 6.9%. The
18-month clinical and MSCT results for the full cohort of 101 patients from the
ABSORB Cohort B trial will be presented.
Conclusion: Eighteen month data are currently being collected and we will present
18-month clinical and MSCT results for the full cohort of patients from the ABSORB
Cohort B trial.
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Background: Very small coronary vessels (reference diameter <2.5mm) are often
associated with diabetic and female patients and remain an important challenge in
interventional cardiology. We studied a large population of patients with very small
vessels treated with Nobori DES coated only abluminally with a matrix of biolimus
A9 and a biodegradable polymer.
Methods: We studied 1284 patients with at least one lesion located in a very small
vessel (SV) treated with Nobori stent. The primary endpoint of the study is target lesion
failure (TLF) defined as cardiac death, target vessel related myocardial infarction (MI)
and target lesion revascularization (TLR). Data are captured electronically with an
extensive monitoring (100% on-line and 30% on-site). An independent clinical event
committee adjudicated all adverse events and an independent corelab analyzes baseline
and adverse events angiograms.
Results: Patients were 65±11 years old, 23% were female, 34.8% had undergone
previous PCI treatment, 52.1% were admitted with acute coronary syndrome, 32.6%
were diabetic (7.6% insulin dependent) and more than 70% were hyperlipidemic and
hypertensive. A mean number of 1.96±1.18 stents were implanted per patient, with
1.67±0.86 lesions per patient treated. Direct stenting was performed in 27.7% of the
procedures and femoral access site was used in 61% of the patients. A total of 69% of
the lesions were complex (type B2+C), 26.4% calcified, 20.0% bifurcated, 10.6% ostial
and 6.3% presented ulceration. By QCA the mean RVD was 2.29±0.48mm. At 2 years,
94.7% of the patients were available for follow-up with reported TLF rate of 3.7% and
stent thrombosis rate of 0.8%.
Conclusion: Although very small vessels are considered challenging to treat and
represent a higher risk for adverse outcomes, this analysis showed very low rates of
TLF and stent thrombosis up to 2 years, indicating excellent efficacy and safety of the
Nobori stent in the treatment of very small vessels.
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Background: The second generation Bioresorbable Everolimus Eluting Vascular
Scaffolds (BVS) are untested at the mid-term follow-up in the subset of small coronary
vessels. We investigated the performance of the second generation BVS (Abbott
Vascular, Santa Clara, CA) in small coronary arteries (<2.5mm) at 1-year follow-up
Methods: The ABSORB Cohort B Trial is a multicentre single-arm, prospective, open-
label trial enrolling 101 patients. In the present post-hoc analysis, the study population
was sorted according to the pre-procedural reference vessel diameter (RVD) into two
groups: 1) Small-vessel group with RVD <2.5mm (41 patients, 41 lesions) and 2)
Large-vessel group with RVD >=2.5 mm (60 patients, 61 lesions). Clinical outcomes
were assessed at one-year follow-up for the entire population and compared between
the two groups. Out of the total population 45 patients were assigned to undergo 6-
month coronary angiography and 56 patients (57 lesions) to have the procedure
performed at one year.
Results: At one-year after implantation no differences in Ischemia-Driven (ID) Major
Adverse Cardiovascular Events (small vessels 3/41 cases, 7.3% vs. large vessels 4/60
cases, 6.7%,p=1.0000), Myocardial Infarction (small vessels 2/41 cases, 4.9% vs large
vessels 1/60 case, 1.7%,p=0.5645) and ID-Target Lesion Revascularization (small
vessels 1/41 case, 2.4% vs large vessels 3/60 cases, 5.0%, p=0.6445) were reported
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